Plain-English translation of NCT03094429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called NaBen can help people with schizophrenia that hasn't responded well to other treatments. You would take NaBen as an add-on to your current clozapine treatment to see if it reduces your remaining symptoms. The study will compare the medication at two different doses against placebo (a pill with no active ingredient).
Many people with schizophrenia continue to struggle with symptoms even after taking clozapine, one of the strongest available antipsychotic medications. Researchers believe this new treatment might help reduce those lingering symptoms by working on a different part of the brain's chemistry.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic multiple times over several months. During the initial screening, researchers will confirm you meet all study requirements. If you qualify, you'll be randomly assigned to take either the new medication at one of two doses or placebo pills, taken twice daily by mouth for 8 weeks. The study has two parts: Part 1 tests which dose works best, and Part 2 (if you continue) confirms the best dose against placebo.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States